Teriparatide Improves Bone and Lipid Metabolism in a Male Rat Model of Type 2 Diabetes Mellitus.

Nomura S, Kitami A, Takao-Kawabata R, Takakura A, Nakatsugawa M, Kono R, Maeno A, Tokuda A, Isogai Y, Ishizuya T, Utsunomiya H, Nakamura M

Endocrinology1 Oct 2019Cited by 24 (Europe PMC)

PMID31504411PMCIDPMC6760306DOI10.1210/en.2019-00239PepBankPUB-31504411

Download PDF PubMedAsk about this study

Jump to 13 results

Summary

Osteoporosis is a complication of diabetes mellitus (DM). The pathology of diabetic osteoporosis is distinct from postmenopausal osteoporosis, and there are no specific treatment guidelines for diabetic osteoporosis. In the current study, this issue was addressed by evaluating the effect of osteoporosis medications, such as the anabolic agent PTH [teriparatide (TPTD)] and the antiresorptive agents calcitonin [elcatonin (ECT)] and bisphosphonate [risedronate (RIS)], on bone metabolism as well as on glucose and lipid metabolism in spontaneously diabetic Torii (SDT) fatty rats, which are a model of type 2 DM (T2DM). The medicines were injected subcutaneously into 8-week-old male SDT fatty rats three times weekly for 8 weeks. TPTD treatment in SDT fatty rats increased the osteoblast number and function on trabecular bone in vertebrae, and increased the trabecular bone mass, bone mineral density (BMD), and mechanical strength of vertebrae. Additionally, TPTD improved cortical bone structure and increased BMD. RIS decreased the osteoclast number and function, which led to an increase in vertebral bone mineral content and BMD in the femoral diaphysis, and mechanical strength was increased in the vertebrae. ECT showed no clear effects on bone mass or metabolism. Similar to diabetic lesions, all of the drugs had no effects on hyperglycemia, pancreas morphology, or serum insulin and glucagon levels. However, triglyceride levels and lipid droplets in fatty liver were decreased in the TPTD group. These results suggest that TPTD may be useful for treating fatty liver in addition to osteoporosis in T2DM.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study13

13 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In diabetic rats, teriparatide increased vertebral trabecular osteoblast number.
In plain wordsIn rats with diabetes, teriparatide increased bone-forming cell numbers in vertebrae.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral osteoblast number
Study
ratn: not reported in source
Male spontaneously diabetic Torii fatty rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
TPTD treatment in SDT fatty rats increased the osteoblast number and function on trabecular bone in vertebrae, and increased the trabecular bone mass, bone mineral density (BMD), and mechanical strength of vertebrae.
1 context sentence(design, population, supporting numbers)
Summary · context
The medicines were injected subcutaneously into 8-week-old male SDT fatty rats three times weekly for 8 weeks.
Show in the study text Report a problemFND-3150441101
02AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, teriparatide increased vertebral trabecular bone mass.
In plain wordsIn rats with diabetes, teriparatide increased vertebral trabecular bone mass.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral trabecular bone mass
Study
ratn: not reported in source
Male spontaneously diabetic Torii fatty rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
TPTD treatment in SDT fatty rats increased the osteoblast number and function on trabecular bone in vertebrae, and increased the trabecular bone mass, bone mineral density (BMD), and mechanical strength of vertebrae.
1 context sentence(design, population, supporting numbers)
Summary · context
The medicines were injected subcutaneously into 8-week-old male SDT fatty rats three times weekly for 8 weeks.
Show in the study text Report a problemFND-3150441102
03AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, teriparatide increased vertebral BMD.
In plain wordsIn rats with diabetes, teriparatide increased vertebral bone density.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral BMD
Study
ratn: not reported in source
Male spontaneously diabetic Torii fatty rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
TPTD treatment in SDT fatty rats increased the osteoblast number and function on trabecular bone in vertebrae, and increased the trabecular bone mass, bone mineral density (BMD), and mechanical strength of vertebrae.
1 context sentence(design, population, supporting numbers)
Summary · context
The medicines were injected subcutaneously into 8-week-old male SDT fatty rats three times weekly for 8 weeks.
Show in the study text Report a problemFND-3150441103
04AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, teriparatide increased vertebral mechanical strength.
In plain wordsIn rats with diabetes, teriparatide increased vertebral strength.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral mechanical strength
Study
ratn: not reported in source
Male spontaneously diabetic Torii fatty rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
TPTD treatment in SDT fatty rats increased the osteoblast number and function on trabecular bone in vertebrae, and increased the trabecular bone mass, bone mineral density (BMD), and mechanical strength of vertebrae.
1 context sentence(design, population, supporting numbers)
Summary · context
The medicines were injected subcutaneously into 8-week-old male SDT fatty rats three times weekly for 8 weeks.
Show in the study text Report a problemFND-3150441104
05AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, teriparatide improved cortical bone structure.
In plain wordsIn rats with diabetes, teriparatide improved cortical bone structure.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical bone structure
Study
ratn: not reported in source
Male spontaneously diabetic Torii fatty rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Additionally, TPTD improved cortical bone structure and increased BMD.
1 context sentence(design, population, supporting numbers)
Summary · context
The medicines were injected subcutaneously into 8-week-old male SDT fatty rats three times weekly for 8 weeks.
Show in the study text Report a problemFND-3150441105
06AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, teriparatide increased cortical BMD.
In plain wordsIn rats with diabetes, teriparatide increased cortical bone density.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical BMD
Study
ratn: not reported in source
Male spontaneously diabetic Torii fatty rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Additionally, TPTD improved cortical bone structure and increased BMD.
1 context sentence(design, population, supporting numbers)
Summary · context
The medicines were injected subcutaneously into 8-week-old male SDT fatty rats three times weekly for 8 weeks.
Show in the study text Report a problemFND-3150441106
07AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, teriparatide had no effect on hyperglycemia.
In plain wordsIn rats with diabetes, teriparatide did not change high blood sugar.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHyperglycemia
Study
ratn: not reported in source
Male spontaneously diabetic Torii fatty rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Similar to diabetic lesions, all of the drugs had no effects on hyperglycemia, pancreas morphology, or serum insulin and glucagon levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The medicines were injected subcutaneously into 8-week-old male SDT fatty rats three times weekly for 8 weeks.
Show in the study text Report a problemFND-3150441107
08AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, teriparatide had no effect on pancreas morphology.
In plain wordsIn rats with diabetes, teriparatide did not change pancreas structure.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePancreas morphology
Study
ratn: not reported in source
Male spontaneously diabetic Torii fatty rats
Outcome group
Islet protection · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Similar to diabetic lesions, all of the drugs had no effects on hyperglycemia, pancreas morphology, or serum insulin and glucagon levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The medicines were injected subcutaneously into 8-week-old male SDT fatty rats three times weekly for 8 weeks.
Show in the study text Report a problemFND-3150441108
09AnimalAnimal study (in vivo)Mechanism
In diabetic rats, teriparatide had no effect on serum insulin.
In plain wordsIn rats with diabetes, teriparatide did not change blood insulin levels.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum insulin
Study
ratn: not reported in source
Male spontaneously diabetic Torii fatty rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Similar to diabetic lesions, all of the drugs had no effects on hyperglycemia, pancreas morphology, or serum insulin and glucagon levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The medicines were injected subcutaneously into 8-week-old male SDT fatty rats three times weekly for 8 weeks.
Show in the study text Report a problemFND-3150441109
10AnimalAnimal study (in vivo)Mechanism
In diabetic rats, teriparatide had no effect on serum glucagon.
In plain wordsIn rats with diabetes, teriparatide did not change blood glucagon levels.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum glucagon
Study
ratn: not reported in source
Male spontaneously diabetic Torii fatty rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Similar to diabetic lesions, all of the drugs had no effects on hyperglycemia, pancreas morphology, or serum insulin and glucagon levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The medicines were injected subcutaneously into 8-week-old male SDT fatty rats three times weekly for 8 weeks.
Show in the study text Report a problemFND-3150441110
11AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, triglyceride levels decreased in the teriparatide group.
In plain wordsIn rats with diabetes, triglyceride levels decreased in the teriparatide group.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTriglycerides
Study
ratn: not reported in source
Male spontaneously diabetic Torii fatty rats
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
However, triglyceride levels and lipid droplets in fatty liver were decreased in the TPTD group.
1 context sentence(design, population, supporting numbers)
Summary · context
The medicines were injected subcutaneously into 8-week-old male SDT fatty rats three times weekly for 8 weeks.
Show in the study text Report a problemFND-3150441111
12AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, lipid droplets in fatty liver decreased in the teriparatide group.
In plain wordsIn rats with diabetes, liver fat droplets decreased in the teriparatide group.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseLiver lipid droplets
Study
ratn: not reported in source
Male spontaneously diabetic Torii fatty rats
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
However, triglyceride levels and lipid droplets in fatty liver were decreased in the TPTD group.
1 context sentence(design, population, supporting numbers)
Summary · context
The medicines were injected subcutaneously into 8-week-old male SDT fatty rats three times weekly for 8 weeks.
Show in the study text Report a problemFND-3150441112
13AnimalAnimal study (in vivo)Mechanism
In diabetic rats, teriparatide increased osteoblast function on vertebral trabecular bone.
In plain wordsIn rats with diabetes, teriparatide increased bone-forming cell function in vertebrae.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral osteoblast function
Study
ratn: not reported in source
Male spontaneously diabetic Torii fatty rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
TPTD treatment in SDT fatty rats increased the osteoblast number and function on trabecular bone in vertebrae, and increased the trabecular bone mass, bone mineral density (BMD), and mechanical strength of vertebrae.
1 context sentence(design, population, supporting numbers)
Summary · context
The medicines were injected subcutaneously into 8-week-old male SDT fatty rats three times weekly for 8 weeks.
Show in the study text Report a problemFND-3150441113

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.